{Reference Type}: Journal Article
{Title}: Clearance of pediatric actinic prurigo with dupilumab.
{Author}: Eickstaedt JB;Starke S;Krakora D;Hinshaw M;Arkin LM;
{Journal}: Pediatr Dermatol
{Volume}: 37
{Issue}: 6
{Year}: Nov 2020
{Factor}: 1.997
{DOI}: 10.1111/pde.14311
{Abstract}: Actinic prurigo is a rare, idiopathic chronic photodermatosis of childhood characterized by excoriated papules, nodules, and plaques in sun-exposed areas. It is notoriously difficult to treat. The disorder involves a type IV hypersensitivity reaction driven by both Th1 and Th2 inflammatory pathways, the latter of which leads to secretion of IL-4, IL-5, IL-13, and production of B cells, IgE, and IgG4. Dupilumab, an IL-4 receptor antagonist, disrupts the Th2 pathway. We present a pediatric patient with severe, recalcitrant actinic prurigo who achieved rapid and sustained clearance with dupilumab.